

Integra	ted Impact Assessment Re	eport for Clinical Commissio	ning Policies
Policy Reference Number	1622		
Policy Title	Lung Volume Reduction for Proposal for routine comm	' '	
Lead Commissioner	Kathy Blacker	Clinical Lead D	David Waller
Finance Lead	Craig Charlton	Analytical Lead	Jacquie Low

	ntegrated Impact Assessment - Index	
Section A – Activity	Section B - Service	Section C – Finance
A1 Current Patient Population & Demography / Growth	B1 Service Organisation	C1 Tariff
A2 Future Patient Population & Demography	B2 Geography & Access	C2 Average Cost per Patient £TBA
A3 Activity	B3 Implementation	C3 Overall Cost Impact of this Policy to NHS England £TBA
A4 Existing Patient Pathway	B4 Collaborative Commissioning	C4 Overall cost impact of this policy to the NHS as a whole
A5 Comparator (next best alternative treatment) Patient Pathway		C5 Funding
A6 New Patient Pathway		C6 Financial Risks Associated with Implementing this Policy
A7 Treatment Setting		C7 Value for Money
A8 Coding		C8 Cost Profile
A9 Monitoring		

About this Impact Assessment: instructions for completion and explanatory notes

- Each section is divided into themes.
- Each theme sets out a number of questions.
- All questions are answered by selecting a drop down option or including free text.
- Free text boxes are provided to enable succinct relevant commentary to be added which explains the rationale for response or assumption. Please limit responses to 3 sentences of explanatory text.
- Data in this document is either drawn from one of the relevant policy documents or a source for the information is provided.
- Where assumptions are included where data is not available, this is specified.

Section A	- Activity Impact
A1 Current Patient Population & Demography / Growth	
A1.1 Prevalence of the disease/condition.	1200 patients meeting the criteria for LVR out of the population with emphysema Source: Policy Proposition section 6
A1.2 Number of patients currently eligible for the treatment according to the proposed policy commissioning criteria.	1200 Source: Policy Proposition section 6required Please specify Click here to enter text.
A1.3 Age group for which the treatment is proposed according to the policy commissioning criteria.	Adults Please specify Click here to enter text.
A1.4 Age distribution of the patient population eligible according to the proposed policy commissioning criteria	enter number. if relevant Source: required Please specify Click here to enter text.
A1.5 How is the population currently distributed geographically?	Evenly If unevenly, estimate regional distribution by %: North enter % Midlands & East enter % London enter %

	South enter %
	Source: Policy Proposition section 6
	Please specify
	Click here to enter text.
A2 Future Patient Population & Demography	
A2.1 Projected changes in the disease/condition epidemiology, such as incidence or prevalence (prior to applying the new policy)	Other - detail below
in 2, 5, and 10 years?	As per ONS growth
	Source: Policy Proposition section 6
A2.2 Are there likely to be changes in demography of the patient	No
population and would this impact on activity/outcomes?	Please specify
	Source: Policy Proposition section 6/other
A2.3 Expected net increase or decrease in the number of patients	YR2 +/- 3
who will be eligible for the service, according to the proposed service specification commissioning criteria, per year in years 2-5	YR3 +/- 6
and 10?	YR4 +/- 9
	YR5 +/- 16
	YR10 +/- 0
	Source: Service specification proposition section 3.1
	Voc
	<u>Yes</u>

Are these numbers in line with ONS growth assumptions for the age specific population? If not please justify the growth assumptions made.	Click here to enter text.
A3 Activity	
A3.1 What is the purpose of new policy?	Confirm routine commissioning position of an additional new treatment Please specify No existing policy
A3.2 What is the annual activity associated with the existing pathway for the eligible population?	300 Source: Click here to enter text. Please specify NCDR extracts
A3.3 What is the estimated annual activity associated with the proposed policy proposition pathway for the eligible population?	Source: financial modelling of clinical view Please specify Assume growth of 180 patients per year for first five years before reaching steady state Areas with well-established pathways to LVR MDTs have not seen significant growth in intervention rates over the last few years. The growth is likely to occur in areas that need these pathways and processes establishing
A3.4 What is the estimated annual activity associated with the next best alternative comparator pathway for the eligible population? If the only alternative is the existing pathway, please state 'not applicable' and move to A4.	Not applicable Source: required Please specify

	Click here to enter text.
A4 Existing Patient Pathway	
A4.1 Existing pathway: Describe the relevant currently routinely commissioned: • Treatment or intervention • Patient pathway • Eligibility and/or uptake estimates.	On the current pathway 300 patients receiving LVR are split 2/3 surgical approach and 1/3 EBV Source: NCDR
A4.2. What are the current treatment access and stopping criteria?	Assessment by LVR Multi-Disciplinary Team into the service. Treatment stopping is completion of treatment
A4.3 What percentage of the total eligible population is expected to: a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	If not known, please specify Click here to enter text. a) 100% b) 66% c) 100% d) 100% e) 100% Source: Clinical experience
A5 Comparator (next best alternative treatment) Patient Pathway (NB: comparator/next best alternative does not refer to current pathway but to an	
A5.1 Next best comparator : Is there another 'next best' alternative treatment which is a relevant comparator?	<u>No</u>

 If yes, describe relevant Treatment or intervention Patient pathway Actual or estimated eligibility and uptake 	If yes, Click here to enter text. Source: required
A5.2 What percentage of the total eligible population is estimated to: a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	Not applicable a) enter % b) enter % c) enter % d) enter % e) enter % Source: required
A6 New Patient Pathway	
A6.1 What percentage of the total eligible population is expected to: a) Be clinically assessed for treatment b) Be considered to meet an exclusion criteria following assessment c) Choose to initiate treatment d) Comply with treatment e) Complete treatment?	If not known, please specify Click here to enter text. a) 100% b) 0 c) 100% d) 100% e) 100% Source: Clinical experience
A6.2 Specify the nature and duration of the proposed new treatment or intervention.	One off For time limited treatments, specify frequency and/or duration. Click here to enter text.

	Source: required		
A7 Treatment Setting			
A7.1 How is this treatment delivered to the patient?	Select all that apply:	1	
	Emergency/Urgent care attendance		
	Acute Trust: inpatient	\boxtimes	
	Acute Trust: day patient		
	Acute Trust: outpatient	\boxtimes	
	Mental Health provider: inpatient		
	Mental Health provider: outpatient		
	Community setting		
	Homecare		
	Other		
	Please specify: Click here to enter text.		
A7.2 What is the current number of contracted providers for the	NORTH		
eligible population by region?	MIDLANDS & EAST		
Craig to check contracted providers	LONDON		
	SOUTH		

A7.3 Does the proposition require a change of delivery setting or capacity requirements?	No Please specify: Click here to enter text. Source: required	
A8 Coding		
A8.1 Specify the datasets used to record the new patient pathway	Select all that apply:	
activity.	Aggregate Contract Monitoring *	
*expected to be populated for all commissioned activity	Patient level contract monitoring	
	Patient level drugs dataset	
	Patient level devices dataset	
	Devices supply chain reconciliation dataset	
	Secondary Usage Service (SUS+)	\boxtimes
	Mental Health Services DataSet (MHSDS)	
	National Return**	
	Clinical Database**	
	Other**	
	**If National Return, Clinical database or other SCTS- NICOR, UK LVR Registry	selected, please specify:
A8.2 Specify how the activity related to the new patient pathway will be identified.	Select all that apply:	

	OPCS v4.8	\boxtimes	
	ICD10	\boxtimes	
	Treatment function code	\boxtimes	
	Main Speciality code	\boxtimes	
	HRG	\boxtimes	
	SNOMED	\boxtimes	
	Clinical coding / terming methodology used by clinical profession		
AC 2 Identification Bulga for Drugge	Not emplicable		
A8.3 Identification Rules for Drugs:	Not applicable		
How are drug costs captured?	If the drug has already been specified in the cu	urrent N	HS England Drug
	List please specify drug name and drug indicate	tion:	
	Click here to enter text.		
	If the drug has NOT already been specified in Drug List please give details of action required been discussed with the pharmacy lead:		
	Click here to enter text.		
A8.4 Identification Rules for Devices:	Not applicable		
How are device costs captured?	If the device is covered by an existing category the Device Category (as per the National Tariff Guidance).		
	Click here to enter text.		
	If the device is not excluded from Tariff nor co National or Local prices please specify details confirm that this has been discussed with the I Click here to enter text.	of action	n required and

A8.5 Identification Rules for Activity: How are activity costs captured?	Already correctly captured by an existing specialised service line (NCBPS code within the PSS Tool NCBPS29B ADULT THORACIC SURGERY SERVICES: COMPLEX THORACIC SURGERY
A9 Monitoring	
A9.1 Contracts Specify any new or revised data flow or data collection requirements, needed for inclusion in the NHS Standard Contract Information Schedule.	Yes - population of clinical databases Please specify SCTS- NICOR, UK LVR Registry
A9.2 Excluded Drugs and Devices (not covered by the Zero Cost Model) For treatments which are tariff excluded drugs or devices not covered by the Zero Cost Model, specify the pharmacy or device monitoring required, for example reporting or use of prior approval systems.	Select all that apply: Drugs or Device MDS Blueteq Other prior approval Please specify: Click here to enter text.
A9.3 Business intelligence Is there potential for duplicate reporting?	No If yes, please specify mitigation: Click here to enter text.
A9.4 Contract monitoring Is this part of routine contract monitoring?	Yes If yes, please specify contract monitoring requirement: Click here to enter text.

A9.5 Dashboard reporting	No No
Specify whether a dashboard exists for the proposed intervention?	If yes, specify how routine performance monitoring data will be used for dashboard reporting.
	Click here to enter text.
	If no, will one be developed?
	Yes
A9.6 NICE reporting	No No
Are there any directly applicable NICE or equivalent quality	If yes, specify how performance monitoring data will be used for this
standards which need to be monitored in association with the new	purpose.
policy?	Click here to enter text.
Section E	B - Service Impact
B1 Service Organisation	
B1 Service Organisation B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.)	Tertiary centres – thoracic services with respiratory services through a joint MDT assessment
B1.1 Describe how the service is currently organised? (i.e. tertiary	
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned	joint MDT assessment
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.)	joint MDT assessment Source: Policy proposition
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned	joint MDT assessment Source: Policy proposition Yes
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned	joint MDT assessment Source: Policy proposition Yes Please specify:
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned	joint MDT assessment Source: Policy proposition Yes Please specify: In some areas changes may be required to ensure joint MDT is in place Source: Policy proposition
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned service is organised?	joint MDT assessment Source: Policy proposition Yes Please specify: In some areas changes may be required to ensure joint MDT is in place Source: Policy proposition No change to delivery of care
B1.1 Describe how the service is currently organised? (i.e. tertiary centres, networked provision etc.) B1.2 Will the proposition change the way the commissioned service is organised? B1.3 Will the proposition require a new approach to the	joint MDT assessment Source: Policy proposition Yes Please specify: In some areas changes may be required to ensure joint MDT is in place Source: Policy proposition

B2.1 Where do current referrals come from?	Select all that apply:		
	GP		
	Secondary care		
	Tertiary care		
	Other		
	Please specify: Click here to enter text.		
B2.2 What impact will the new policy have on the sources of referral?	No impact Please specify: Click here to enter text.		
B2.3 Is the new policy likely to improve equity of access?	Increase Please specify: Currently there is geogra Source: Equalities Impa	•	
B2.4 Is the new policy likely to improve equality of access and/or outcomes?	Increase Please specify: Address geographical in Source: Equalities Impa	• •	

B3 Implementation	
B3.1 Will commissioning or provider action be required before implementation of the proposition can occur?	Contract action Please specify: In some areas patient pathways to and from LVR MDT may need confirmation
B3.2 Time to implementation: Is a lead-in time required prior to implementation?	No - go to B3.4 If yes, specify the likely time to implementation: Enter text
B3.3 Time to implementation: If lead-in time is required prior to implementation, will an interim plan for implementation be required?	Choose an item. If yes, outline the plan: Click here to enter text.
B3.4 Is a change in provider physical infrastructure required?	No Please specify: Use of existing theatres and bronchoscopy facilities
B3.5 Is a change in provider staffing required?	No Please specify: Click here to enter text.
B3.6 Are there new clinical dependency and/or adjacency requirements that would need to be in place?	Yes Please specify: Thoracic services and respiratory services must work together to establish joint MDT for appropriate patient selection

B3.7 Are there changes in the support services that need to be in place?	No Please specify: Click here to enter text.				
B3.8 Is there a change in provider and/or inter-provider governance required? (e.g. ODN arrangements / prime contractor)	Yes Please specify: Thoracic and respiratory services will need to establish governance arrangements. They may not always be the same provider.				
B3.9 Is there likely to be either an increase or decrease in the number of commissioned providers? If yes, specify the current and estimated number of providers required in each region	No change Please complete table:				
	Region	Current no. of providers	Future State expected range	Provisional or confirmed	
	North			select	
	Midlands & East			select	
	London			select	
	South			select	
	Total			select	I
	Please specify Click here to 6	•			
B3.10 Specify how revised provision will be secured by NHS England as the responsible commissioner.	Select all tha	at apply:			
	Publication a	and notification of	new policy		
	Market interv	vention required			

		ve selection process to secure increase or provider configuration		
	Price-bas effectiven	ed selection process to maximise cost		
	Any qualif	ied provider		
	National (Commercial Agreements e.g. drugs, devices		
	Procurem	ent		
	Other		\boxtimes	
	Please spe Click here	ecify: to enter text.		
B4 Place-based Commissioning				
B4.1 Is this service currently subject to, or planned for, place-based commissioning arrangements? (e.g. future CCG lead, devolved commissioning arrangements, STPs)	No Please spe Click here	ecify: to enter text.		
Section C - Finance Impact				
C1 Tariff/Pricing				
C1.1 How is the service contracted and/or charged?	Select all	that apply:		
Only specify for the relevant section of the patient pathway	Drugs	Not separately charged – part of local or nati tariffs	ional	\boxtimes
		Excluded from tariff – pass through		

		Excluded from tariff - other	
	Devices	Not separately charged – part of local or national tariffs	\boxtimes
		Excluded from tariff (excluding ZCM) - pass through	
		Excluded from tariff (excluding ZCM) - other	
		Via Zero Cost Model	
		Paid entirely by National Tariffs	\boxtimes
		Paid entirely by Local Tariffs	
		Partially paid by National Tariffs	
	Activity	Partially paid by Local Tariffs	
		Part/fully paid under a Block arrangement	
		Part/fully paid under Pass-Through arrangements	
		Part/fully paid under Other arrangements	
C1.2 Drug Costs Where not included in national or local tariffs, list each drug or combination, dosage, quantity, list price including VAT if applicable and any other key information e.g. Chemotherapy Regime. NB discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.	N/A		
C1.3 Device Costs	N/A		

Where not included in national or local tariff, list each element of the excluded device, quantity, list or expected price including VAT if applicable and any other key information. NB: Discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.		
C1.4 Activity Costs covered by National Tariffs List all the HRG codes, HRG descriptions, national tariffs (excluding MFF), volume and other key costs (e.g. specialist top up %)	Surgical procedures would be covered under the following HRGs 2018/19 HRG & Description Tariff	
	TBA TBA	
C1.5 Activity Costs covered by Local Tariff List all the HRGs (if applicable), HRG or local description, estimated average tariff, volume and any other key costs. Also indicate whether the Local Tariff(s) is/are newly proposed or established and if newly proposed how is has been derived, validated and tested.	N/A	
C1.6 Other Activity Costs not covered by National or Local Tariff Include descriptions and estimates of all key costs.	N/A	
C1.7 Are there any prior approval mechanisms required either during implementation or permanently?	<u>No</u>	

	Please specify: Click here to enter text.
C2 Average Cost per Patient	
C2.1 What is the estimated cost per patient to NHS England, in years 1-5, including follow-up where required? Are there any changes expected in year 6-10 which would impact the model?	YR1 £TBC YR2 £TBC YR3 £TBC YR4 £TBC YR5 £TBC
C3 Overall Cost Impact of this Policy to NHS England	Click here to enter text.
C3.1 Specify the budget impact of the proposal on NHS England in relation to the relevant pathway.	Cost pressure Please specify: £TBC Click here to enter text.
C3.2 If the budget impact on NHS England cannot be identified set out the reasons why this cannot be measured.	Click here to enter text.

C3.3 If the activity is subject to a change of commissioning responsibility, from CCG to NHS England, has a methodology for the transfer of funds been identified, and calculated?	Click here to enter text.
C4 Overall cost impact of this policy to the NHS as a whole	
C4.1 Specify the budget impact of the proposal on other parts of the NHS.	Budget impact for CCGs: Cost saving Budget impact for providers: Cost neutral Please specify: Click here to enter text.
C4.2 Taking into account responses to C3.1 and C4.1, specify the budget impact to the NHS as a whole.	Cost pressure Please specify: Click here to enter text.
C4.3 Where the budget impact is unknown set out the reasons why this cannot be measured	N/A
C4.4 Are there likely to be any costs or savings for non-NHS commissioners and/or public sector funders?	No Please specify: Click here to enter text.
C5 Funding	

C5.1 Where a cost pressure is indicated, state known source of funds for investment, where identified, e.g. decommissioning less clinically or cost-effective services.	Specialised Commissioning CPAG Funding decision
C6 Financial Risks Associated with Implementing this Policy	
C6.1 What are the material financial risks to implementing this policy?	Risks associated with the increase in patient numbers profiled across five years and subsequently amending the ratio over the first two financial years
C6.2 How can these risks be mitigated?	Consideration of patient phasing
C6.3 What scenarios (differential assumptions) have been explicitly tested to generate best case, worst case and most likely total cost scenarios?	The model can be amended to reflect patient number and phasing changes
C6.4 What scenario has been approved and why?	Growth from current 300 patients to 1200 patients by year 5 and the split changing from 66% surgery and 34% EBV to a 50/50 split by year 3 of the policy.
C7 Value for Money	
C7.1 What published evidence is available that the treatment is cost effective as evidenced in the evidence review?	There is no published evidence of cost-effectiveness Please specify: Click here to enter text.

C7.2 Has other data been identified through the service specification development relevant to the assessment of value for money?	Select all that apply:			
	Available pricing data suggests the treatment is equivalent cost compared to current/comparator treatment			
	Available pricing data suggests the treatment is lower cost compared to current/comparator treatment			
	Available clinical practice data suggests the new treatment has the potential to improve value for money			
	Other data has been identified			
	No data has been identified			
	The data supports a high level of certainty about the impact on value			
	The data does not support a high level of certainty about the impact on value			
	Please specify:			
	N/A			
	Click here to enter text.			
C8 Cost Profile				
C8.1 Are there non-recurrent capital or revenue costs associated	<u>No</u>			
with this policy?	If yes, specify type and range:			
	Click here to enter text.			
C8.2 If yes, confirm the source of funds to meet these costs.	Click here to enter text.			